SOLIRIS 10 MG
ECULIZUMAB : 10 MG · DIN 02322285 · ALEXION PHARMA GMBH
Health Canada status: MARKETED
What is SOLIRIS?
SOLIRIS 10 MG contains ECULIZUMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02322285, held by ALEXION PHARMA GMBH, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Sep-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SOLIRIS used for?
SOLIRIS (eculizumab for injection) is indicated for: • Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab for injection) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. • Atypical Hemolytic Uremic Syndrome (atypical HUS) Soliris (eculizumab for injection) is indicated for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to reduce complement - mediated thrombotic microangiopathy. • Generalized Myasthenia Gravis (gMG) Soliris (eculizumab for injection) is indicated in adult patients with generalized Myasthenia Gravis (gMG). • Neuromyelitis Optica Spectrum Disorder (NMOSD) Soliris (eculizumab for injection) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti - aquaporin - 4 (AQP4) antibody positive.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02322285 |
|---|---|
| Brand name | SOLIRIS |
| Generic / active ingredient | ECULIZUMAB : 10 MG |
| Manufacturer | ALEXION PHARMA GMBH |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L04AJ01 ECULIZUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Sep-2013 |
How is it stored and handled?
null
How is it supplied?
30-mL single-use vials, Each carton contains one vial.
Who else supplies ECULIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ECULIZUMAB appears in 23 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.